MELBOURNE, Australia, Feb. 24 /Medianet International-AsiaNet/ --
Gordagen Pharmaceuticals, an Australian nutraceutical and pharmaceutical company, is pleased to announce a collaborative research agreement with Monash University to assess a new drug delivery technology.
The research project will assess the feasibility of using a novel, patent-pending lymph directing drug delivery technology. The technology was developed by researchers at the ARC Centre of Excellence in Convergent Bio-Nano Science and Technology based at the Monash Institute for Pharmaceutical Sciences, Australia's leading Institute in drug delivery and drug discovery. It is anticipated that the technology will help improve the bioavailability of tocotrienols, which forms the basis of Gordagen's prescription medicines portfolio.
No comments:
Post a Comment